Floatz logo

Xmab808

Ovarian Cancer, Epithelial

Xencor, Inc.Phase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

244 Active assets in the Ovarian Cancer, Epithelial cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

Xmab808 is also rated in:

nonpapillary renal cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
castration-resistant prostate carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
urothelial carcinomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →